241 related articles for article (PubMed ID: 20600013)
1. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.
Zeuzem S; Sulkowski MS; Lawitz EJ; Rustgi VK; Rodriguez-Torres M; Bacon BR; Grigorescu M; Tice AD; Lurie Y; Cianciara J; Muir AJ; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG;
Gastroenterology; 2010 Oct; 139(4):1257-66. PubMed ID: 20600013
[TBL] [Abstract][Full Text] [Related]
2. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.
Nelson DR; Benhamou Y; Chuang WL; Lawitz EJ; Rodriguez-Torres M; Flisiak R; Rasenack JW; Kryczka W; Lee CM; Bain VG; Pianko S; Patel K; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG;
Gastroenterology; 2010 Oct; 139(4):1267-76. PubMed ID: 20600017
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.
Pianko S; Zeuzem S; Chuang WL; Foster GR; Sarin SK; Flisiak R; Lee CM; Andreone P; Piratvisuth T; Shah S; Sood A; George J; Gould M; Komolmit P; Thongsawat S; Tanwandee T; Rasenack J; Li Y; Pang M; Yin Y; Feutren G; Jacobson IM;
J Viral Hepat; 2012 Sep; 19(9):623-34. PubMed ID: 22863266
[TBL] [Abstract][Full Text] [Related]
4. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.
Zeuzem S; Yoshida EM; Benhamou Y; Pianko S; Bain VG; Shouval D; Flisiak R; Rehak V; Grigorescu M; Kaita K; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG
Hepatology; 2008 Aug; 48(2):407-17. PubMed ID: 18666223
[TBL] [Abstract][Full Text] [Related]
5. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.
Foster GR; Zeuzem S; Pianko S; Sarin SK; Piratvisuth T; Shah S; Andreone P; Sood A; Chuang WL; Lee CM; George J; Gould M; Flisiak R; Jacobson IM; Komolmit P; Thongsawat S; Tanwandee T; Rasenack J; Sola R; Messina I; Yin Y; Cammarata S; Feutren G; Brown KK
J Viral Hepat; 2013 Apr; 20(4):e115-23. PubMed ID: 23490379
[TBL] [Abstract][Full Text] [Related]
6. Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.
Nelson DR; Rustgi V; Balan V; Sulkowski MS; Davis GL; Muir AJ; Lambiase LR; Dickson RC; Weisner RH; Fiscella M; Cronin PW; Pulkstenis E; McHutchison JG; Subramanian GM
Clin Gastroenterol Hepatol; 2009 Feb; 7(2):212-8. PubMed ID: 19061971
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.
Laguno M; Cifuentes C; Murillas J; Veloso S; Larrousse M; Payeras A; Bonet L; Vidal F; Milinkovic A; Bassa A; Villalonga C; Pérez I; Tural C; Martínez-Rebollar M; Calvo M; Blanco JL; Martínez E; Sánchez-Tapias JM; Gatell JM; Mallolas J
Hepatology; 2009 Jan; 49(1):22-31. PubMed ID: 19085908
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.
Villa E; Cammà C; Di Leo A; Karampatou A; Enea M; Gitto S; Bernabucci V; Losi L; De Maria N; Lei B; Ferrari A; Vukotic R; Vignoli P; Rendina M; Francavilla A
J Viral Hepat; 2012 Sep; 19(9):640-9. PubMed ID: 22863268
[TBL] [Abstract][Full Text] [Related]
9. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
[TBL] [Abstract][Full Text] [Related]
11. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.
Brady DE; Torres DM; An JW; Ward JA; Lawitz E; Harrison SA
Clin Gastroenterol Hepatol; 2010 Jan; 8(1):66-71.e1. PubMed ID: 19747986
[TBL] [Abstract][Full Text] [Related]
12. Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C.
Neumann AU; Bain VG; Yoshida EM; Patel K; Pulkstenis E; Subramanian GM
Liver Int; 2009 Oct; 29(9):1350-5. PubMed ID: 19291180
[TBL] [Abstract][Full Text] [Related]
13. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P
Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315
[TBL] [Abstract][Full Text] [Related]
14. Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study.
Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
J Interferon Cytokine Res; 2008 Oct; 28(10):623-9. PubMed ID: 18778199
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
[TBL] [Abstract][Full Text] [Related]
17. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
McHutchison J; Sulkowski M
J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
19. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.
Wirth S; Ribes-Koninckx C; Calzado MA; Bortolotti F; Zancan L; Jara P; Shelton M; Kerkar N; Galoppo M; Pedreira A; Rodriguez-Baez N; Ciocca M; Lachaux A; Lacaille F; Lang T; Kullmer U; Huber WD; Gonzalez T; Pollack H; Alonso E; Broue P; Ramakrishna J; Neigut D; Valle-Segarra AD; Hunter B; Goodman Z; Xu CR; Zheng H; Noviello S; Sniukiene V; Brass C; Albrecht JK
J Hepatol; 2010 Apr; 52(4):501-7. PubMed ID: 20189674
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]